EXPLOITING NOVEL THERAPEUTIC TARGETS IN MULTIPLE MYELOMA (K23M)

探索多发性骨髓瘤 (K23M) 的新治疗靶点

• 批准号: 7088988
• 负责人: RUBEN NIESVIZKY
• 金额: $ 13.61万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-02 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7088988
• 关键词: amidohydrolases; antineoplastics; apoptosis; cell growth regulation; cell line; clarithromycin; clinical research; clinical trial phase II; combination chemotherapy; dexamethasone; drug screening /evaluation; enzyme inhibitors; experimental designs; genetic regulation; genetic transcription; human subject; human therapy evaluation; immunocytochemistry; microarray technology; multiple myeloma; neoplasm /cancer chemotherapy; neoplastic cell; patient oriented research; pharmacokinetics

DESCRIPTION (provided by applicant): Development of novel therapeutic strategies in myeloma and other B-cell malignancies requires collaborative efforts between clinical researchers and basic scientists. There is a clear need for individuals with skills in patients care, clinical trial design, and basic science principles who can bridge the gap between the bench and the bedside in the conception, development and evaluation of new treatment in these and other forms of cancer. As the principal investigator in this project, Dr Niesvizky is dedicated to further his research activities and undergo further mentored training for his career development to fill this long-term role. In order to attain the necessary skills, the strategy is to follow an educational and research path including: 1) Development and execution of a translational study to evaluate the effect of selected promising agents in the treatment of multiple myeloma under the tutoring of Drs. Bergsagel and Chen-Kiang. 2) Didactic and mentored training in clinical trial design with Dr Scott Wadler, as well as through several institutional resources including the General Clinical Research Center and the Weill Graduate School of Medical Sciences of Cornell University. 3)Development and execution of investigator-initiated clinical trials for myeloma using novel agents and combinations. Dr Niesvizky's research is focused in drug development. Following this five-year comprehensive program, he will attain the independent clinical research skills to work with basic science collaborators to lead a translational research program in drug development and other novel treatments for myeloma. It is expected that this work will significantly contribute to the care of patients with this disease and other B-cell malignancies.

描述（由申请人提供）：骨髓瘤和其他 B 细胞恶性肿瘤的新型治疗策略的开发需要临床研究人员和基础科学家之间的合作努力。 显然需要具有患者护理、临床试验设计和基础科学原理技能的个人，他们可以在这些和其他形式的癌症的新疗法的构思、开发和评估方面弥合实验室和床边之间的差距。 作为该项目的首席研究员，Niesvizky 博士致力于进一步开展他的研究活动，并接受进一步的职业发展指导培训，以填补这一长期角色。 为了获得必要的技能，该策略是遵循教育和研究路径，包括： 1) 在 Drs. 的指导下开发和执行一项转化研究，以评估选定的有前景药物在治疗多发性骨髓瘤中的效果。伯格萨格尔和陈江。 2) 由 Scott Wadler 博士以及包括普通临床研究中心和康奈尔大学威尔医学科学研究生院在内的多个机构资源进行临床试验设计方面的说教和指导培训。 3) 使用新型药物和组合开发和执行研究者发起的骨髓瘤临床试验。 Niesvizky 博士的研究重点是药物开发。 在这个为期五年的综合计划之后，他将获得独立的临床研究技能，与基础科学合作者合作，领导药物开发和其他骨髓瘤新疗法的转化研究计划。 预计这项工作将为患有这种疾病和其他 B 细胞恶性肿瘤的患者的护理做出重大贡献。